Japan Clinical Oncology Group (JCOG)

被引:29
作者
Shimoyama, M [1 ]
Fukuda, H [1 ]
Saijo, N [1 ]
Yamaguchi, N [1 ]
机构
[1] Nagoya Natl Hosp, Dept Internal Med, Naka Ku, Nagoya, Aichi 4600001, Japan
关键词
JCOG; clinical trial; committee; data center; statistical center;
D O I
10.1093/jjco/28.3.158
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Japan Clinical Oncology Group (JCOG) is a cooperative oncology group with the aims of conducting, developing, coordinating and stimulating clinical research in Japan on the treatment of cancer and related problems, The purpose of JCOG is to establish and improve the standard of cancer treatment, mainly in solid cancer, through the testing of new therapeutic regimens or combined modalities, using drugs that are newly-approved or already commercially available. Research sponsored by JCOG is accomplished mainly through the execution of large, prospective, randomized, multicenter, clinical trials, In this way, JCOG facilitates the passage of new clinical trial discoveries into state-of-the-art treatment.
引用
收藏
页码:158 / 162
页数:5
相关论文
共 57 条
[1]   A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study [J].
Ando, N ;
Iizuka, T ;
Kakegawa, T ;
Isono, K ;
Watanabe, H ;
Ide, H ;
Tanaka, O ;
Shinoda, M ;
Takiyama, W ;
Arimori, M ;
Ishida, K ;
Tsugane, S .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (02) :205-209
[2]  
ARIYOSHI Y, 1994, JPN J CLIN ONCOL, V24, P275
[3]   STUDY OF DOSE-ESCALATION OF TENIPOSIDE (VM-26) PLUS CISPLATIN (CDDP) WITH RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) IN PATIENTS WITH ADVANCED SMALL-CELL LUNG-CANCER [J].
EGUCHI, K ;
ETOU, H ;
MIYACHI, S ;
MORINARI, H ;
NAKADA, K ;
NODA, K ;
OHKUNI, Y ;
WATANABE, K ;
YAMADA, Y ;
OHE, Y ;
TAMURA, T ;
SASAKI, Y ;
SHINKAI, T ;
SAIJO, N .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (02) :188-194
[4]  
FUKUHARA S, 1993, CANC CHEMOTHERAPY CH, V8, P289
[5]   CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer [J].
Fukuoka, M ;
Masuda, N ;
Negoro, S ;
Matsui, K ;
Yana, T ;
Kudoh, S ;
Kusunoki, Y ;
Takada, M ;
Kawahara, M ;
Ogawara, N ;
Kodama, N ;
Kubota, K ;
Furuse, K .
BRITISH JOURNAL OF CANCER, 1997, 75 (02) :306-309
[6]   RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE VERSUS CISPLATIN AND ETOPOSIDE VERSUS ALTERNATION OF THESE REGIMENS IN SMALL-CELL LUNG-CANCER [J].
FUKUOKA, M ;
FURUSE, K ;
SAIJO, N ;
NISHIWAKI, Y ;
IKEGAMI, H ;
TAMURA, T ;
SHIMOYAMA, M ;
SUEMASU, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (12) :855-861
[7]   RANDOMIZED STUDY WITH MITOMYCIN-C PLUS 5-FLUOROURACIL PLUS CYTOSINE-ARABINOSIDE (MFC) PLUS 5-FLUOROURACIL, MFC PLUS TEGAFUR AND URACIL (UFT), AND MF PLUS UFT IN ADVANCED GASTRIC-CANCER - INTERINSTITUTIONAL DIFFERENCES IN A MULTICENTER STUDY IN JAPAN [J].
FURUKAWA, H ;
IWANAGA, T ;
NAKAJIMA, T ;
OKABAYASHI, K ;
NAKAZATO, H ;
HIRATSUKA, M ;
OHTA, K ;
KITO, T ;
YAMAMURA, Y ;
GOTO, S .
JOURNAL OF SURGICAL ONCOLOGY, 1995, 60 (01) :59-64
[8]  
IIZUKA T, 1991, JPN J CLIN ONCOL, V21, P176
[9]  
IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172
[10]   PREOPERATIVE RADIOACTIVE THERAPY FOR ESOPHAGEAL-CARCINOMA - RANDOMIZED EVALUATION TRIAL IN 8 INSTITUTIONS [J].
IIZUKA, T ;
IDE, H ;
KAKEGAWA, T ;
SASAKI, K ;
TAKAGI, I ;
ANDO, N ;
MORI, S ;
ARIMORI, M ;
TSUGANE, S .
CHEST, 1988, 93 (05) :1054-1058